Restart Life Sciences stock analysis
Restart Life Sciences (HN30) Stock Price & Analysis
HN30 Stock Chart & Stats
- Day’s Range
- EUR 0.04 - EUR 0.04
- 52-Week Range
- EUR 0.04 - EUR 0.08
- Previous Close
- EUR 0.04
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 2.58M
- Enterprise Value
- EUR 4.75M
- Total Cash (Recent Filing)
- EUR 762.36K
- Total Debt (Recent Filing)
- EUR 348.35K
- Price to Earnings (P/E)
- ―
- Beta
- 1.30
- Next Earnings
- Dec 02, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Stabilization
The return to positive equity and relatively modest 2025 leverage represent a meaningful improvement in financial positioning. This provides more flexibility than the prior negative-equity periods, although the benefit is tempered by the company’s history of balance-sheet volatility.
Improving Cash Burn Trend
Although cash flow remains negative, the reduced magnitude of outflows versus the 2021–2022 trough indicates some improvement in cash consumption. If maintained, this trend could extend the company’s financial runway and reduce the pace at which external funding is required.
Asset Base Rebuilding
A meaningful asset base relative to prior years suggests that the company has rebuilt part of its financial resources. This can support future operations and strategic development, provided the assets contribute to a credible path toward revenue generation and improved cash economics.
Bears Say
Absent Recurring Revenue
The absence of recurring revenue is a fundamental weakness because it shows that the business has not yet demonstrated commercial traction or a dependable source of operating inflows. Without revenue generation, funding growth and validating the business model remain difficult over the medium term.
Persistent Operating Losses
Recurring negative EBIT and EBITDA indicate that core operations are not yet economically viable. This limits internal reinvestment capacity and means any future expansion must occur before operating profitability is established, increasing dependence on financing or other non-operating sources.
Continued Cash Dependence
Persistent negative operating and free cash flow shows that the company is still consuming cash rather than funding itself through operations. Continued cash burn implies reliance on external capital, which can constrain strategic flexibility and make sustained execution harder if funding needs persist.
Restart Life Sciences News
HN30 FAQ
What was Restart Life Sciences’s price range in the past 12 months?
What is Restart Life Sciences’s market cap?
When is Restart Life Sciences’s upcoming earnings report date?
How were Restart Life Sciences’s earnings last quarter?
Is Restart Life Sciences overvalued?
Does Restart Life Sciences pay dividends?
What is Restart Life Sciences’s EPS estimate?
How many shares outstanding does Restart Life Sciences have?
What happened to Restart Life Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Restart Life Sciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steve Loutskou
- Employees
- 3
- Website
- www.restartlife.co
- Address
- 700-838 West Hasting Street, Vancouver, BC, V6C 0A6, CA
Restart Life Sciences (HN30) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |




